ARDS

Category

Icahn School of Medicine at Mount Sinai Drives Collaborative Investigation into use of Nintedanib in COVID-19 Patients with Fibrosing ILD

New York City’s preeminent Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office (CTO) and collaborative partner Boehringer Ingelheim, the world’s largest privately held pharmaceutical company based in Germany, announced that the...

Physician in Savannah, Georgia, Embraces Investigational Regenerative Acellular-based Therapy to Treat COVID-19 Long Haulers on FDA Expanded Access Protocol

With over 12 million COVID-19 cases and growing, some physicians become ever more open and innovative in their quest to treat their patients. Take Dr. Allen Meglin, practicing in Savannah, Georgia, who now has internalized the need to deal with the frightening next...

Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform

Novartis recently inked an exclusive worldwide license and collaboration agreement with regenerative therapy venture Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that...

FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe

South Korean-based Enzychem Lifesciences (KOSDAQ: 183490) just announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in...

At-Home Decentralized COLCORONA Trial Investigates if Colchicine Keeps COVID-19 Symptoms from Progressing to Reduce Hospitalization & Death

There is presently no available, FDA-approved medicine that can be administered at a patient’s home that can prevent the negative progression of SARS-CoV-2 symptoms leading to hospitalization and potentially death. Can a widely available, generic drug used for gout...

Canada Health Greenlights Clinical Trial Investigating NuvOx’s Oxygen Therapeutic as a Treatment for COVID-19-based AHRF

NuvOX Pharma, a Tucson Arizona-based biotechnology company, received the green light in the form of a “No Objection Letter” form Health Canada to initiate a Phase 2a clinical trial investigating NanO2 in COVID-19 patients with acute hypoxic respiratory failure (AHRF)....

Pin It on Pinterest